E.D. Kreuser

1.7k total citations
48 papers, 1.2k citations indexed

About

E.D. Kreuser is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, E.D. Kreuser has authored 48 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Pathology and Forensic Medicine. Recurrent topics in E.D. Kreuser's work include Colorectal Cancer Treatments and Studies (11 papers), Cancer Treatment and Pharmacology (8 papers) and Genetic factors in colorectal cancer (7 papers). E.D. Kreuser is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Cancer Treatment and Pharmacology (8 papers) and Genetic factors in colorectal cancer (7 papers). E.D. Kreuser collaborates with scholars based in Germany, United States and Switzerland. E.D. Kreuser's co-authors include М. Р. Личиницер, В. А. Горбунова, Ingo Diel, B. Bergström, M. Budde, Jean‐Jacques Body, W. Dornoff, E. Thiel, Michael Streit and Heribert Stauder and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

E.D. Kreuser

44 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E.D. Kreuser Germany 18 797 219 212 207 202 48 1.2k
Stella D’Oronzo Italy 21 594 0.7× 124 0.6× 176 0.8× 77 0.4× 421 2.1× 46 1.1k
Johanna G. H. van Nes Netherlands 16 681 0.9× 96 0.4× 104 0.5× 160 0.8× 288 1.4× 31 1.2k
Herbert Stoeger Austria 17 848 1.1× 206 0.9× 83 0.4× 81 0.4× 333 1.6× 33 1.3k
A M Ballesta Spain 17 508 0.6× 149 0.7× 171 0.8× 82 0.4× 351 1.7× 32 930
Daniel Egle Austria 18 1.0k 1.3× 123 0.6× 167 0.8× 81 0.4× 990 4.9× 88 2.3k
Elena Verri Italy 17 711 0.9× 133 0.6× 156 0.7× 31 0.1× 324 1.6× 55 1.2k
Ewa Kalinka‐Warzocha Poland 18 504 0.6× 69 0.3× 81 0.4× 117 0.6× 160 0.8× 91 944
Ngan‐Ming Tsang Taiwan 20 553 0.7× 159 0.7× 240 1.1× 68 0.3× 378 1.9× 57 1.3k
Annette Fisseler‐Eckhoff Germany 22 472 0.6× 99 0.5× 324 1.5× 75 0.4× 254 1.3× 92 1.5k
Véronique D’Hondt France 21 781 1.0× 110 0.5× 144 0.7× 102 0.5× 298 1.5× 83 1.3k

Countries citing papers authored by E.D. Kreuser

Since Specialization
Citations

This map shows the geographic impact of E.D. Kreuser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.D. Kreuser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.D. Kreuser more than expected).

Fields of papers citing papers by E.D. Kreuser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.D. Kreuser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.D. Kreuser. The network helps show where E.D. Kreuser may publish in the future.

Co-authorship network of co-authors of E.D. Kreuser

This figure shows the co-authorship network connecting the top 25 collaborators of E.D. Kreuser. A scholar is included among the top collaborators of E.D. Kreuser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.D. Kreuser. E.D. Kreuser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Streit, Markus, et al.. (2008). Inzidenz und Signifikanz therapie-assoziierter Spättoxizität bei Morbus Hodgkin. DMW - Deutsche Medizinische Wochenschrift. 120(31/32). 1093–1099.
2.
Kreuser, E.D., et al.. (2008). Fibrinpleurodese bei malignen Pleuraergüssen. DMW - Deutsche Medizinische Wochenschrift. 110(36). 1365–1368.
3.
Serin, D., Mark Verrill, Andrew Jones, et al.. (2005). Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study. British Journal of Cancer. 92(11). 1989–1996. 10 indexed citations
4.
Diel, Ingo, Jean‐Jacques Body, М. Р. Личиницер, et al.. (2004). Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer. 40(11). 1704–1712. 112 indexed citations
5.
Body, Jean‐Jacques, Ingo Diel, М. Р. Личиницер, et al.. (2003). Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology. 14(9). 1399–1405. 296 indexed citations
6.
Stauder, Heribert & E.D. Kreuser. (2002). Mistletoe Extracts Standardised in terms of Mistletoe Lectins (ML I) in Oncology: Current State of Clinical Research. Oncology Research and Treatment. 25(4). 374–380. 44 indexed citations
7.
Hartung, G., Ralf‐Dieter Hofheinz, A. Wein, et al.. (2001). Phase II Study of a Weekly 24-Hour Infusion with 5-Fluorouracil and Simultaneous Sodium – Folinic Acid in the First-Line Treatment of Metastatic Colorectal Cancer. Oncology Research and Treatment. 24(5). 457–462. 12 indexed citations
8.
9.
Link, K. H., et al.. (1997). Acceptance and Toxicity of Postoperative Adjuvant Therapy in Colon and Rectal Cancers. Oncology Research and Treatment. 20(3). 235–238. 9 indexed citations
10.
Eckert, Klaus, et al.. (1997). Prothymosin α1 effects, in vitro, on the antitumor activity and cytokine production of blood monocytes from colorectal tumor patients. International Journal of Immunopharmacology. 19(6). 323–332. 19 indexed citations
11.
Herzberg, Frank, et al.. (1996). IL-4 and TNF-? induce changes in integrin expression and adhesive properties and decrease the lung-colonizing potential of HT-29 colon carcinoma cells. Clinical & Experimental Metastasis. 14(2). 165–175. 17 indexed citations
12.
Goldin-Lang, Petra, E.D. Kreuser, & H.‐J. Zunft. (1996). Basis and Consequences of Primary and Secondary Prevention of Gastrointestinal Tumors. Recent results in cancer research. 142. 163–192. 5 indexed citations
13.
Streit, Michael, et al.. (1996). Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. Journal of Molecular Medicine. 74(5). 253–268. 33 indexed citations
14.
Herrmann, Richard, K. Mross, Ulrich R. Kleeberg, et al.. (1995). 4′-lodo-4′-Deoxydoxorubicin (IDX) in Colorectal Cancer – A Multicenter Phase II Study. Oncology Research and Treatment. 18(1). 28–30. 1 indexed citations
15.
Streit, Michael, E.D. Kreuser, Ute Harms, et al.. (1994). Quantifying Cell Adhesion of the Colon Cancer Cell Line HT 29 to Extracellular Matrix Proteins: Comparative Evaluation of an Isotopic, a Fluorometric, and a Colorimetric Method. Oncology Research and Treatment. 17(5). 528–537. 1 indexed citations
16.
Weh, H.J., H. Wilke, Judith Dierlamm, et al.. (1994). Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Annals of Oncology. 5(3). 233–237. 65 indexed citations
17.
Kreuser, E.D., et al.. (1993). The Role of LHRH-Analogues inProtecting Gonadal Functionsduring Chemotherapy andIrradiation. European Urology. 23(1). 157–164. 32 indexed citations
18.
Kreuser, E.D., et al.. (1992). A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.. PubMed. 19(2 Suppl 3). 197–203. 18 indexed citations
19.
Kreuser, E.D., et al.. (1990). Gonadal toxicity following cancer therapy in adults: significance, diagnosis, prevention and treatment. Cancer Treatment Reviews. 17(2-3). 169–175. 21 indexed citations
20.
Peest, D., H. Deicher, R. Coldewey, et al.. (1990). Melphalan and Prednisone (MP) versus Vincristine, BCNU, Adriamycin, Melphalan and Dexamethasone (VBAMDex) Therapy for Multiple Myeloma. Oncology Research and Treatment. 13(1). 43–44.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stella D’Oronzo Breakdown of academic impact, for papers by Johanna G. H. van Nes Breakdown of academic impact, for papers by Herbert Stoeger Breakdown of academic impact, for papers by A M Ballesta Breakdown of academic impact, for papers by Daniel Egle Breakdown of academic impact, for papers by Elena Verri Breakdown of academic impact, for papers by Ewa Kalinka‐Warzocha Breakdown of academic impact, for papers by Ngan‐Ming Tsang Breakdown of academic impact, for papers by Annette Fisseler‐Eckhoff Breakdown of academic impact, for papers by Véronique D’Hondt
Rankless by CCL
2026